How Much Can ISRG Stock Still Move Against You?

Intuitive Surgical (ISRG) has handed its owners a hard year. The stock is down 25% over the trailing twelve months while the S&P 500 returned 19.3%, and it now trades about 41% below its 52-week high. After a fall like that the natural hope is that the big moves are behind you. Options priced a year out say they are not.

Options Are Pricing Two-In-Three Odds Of $240 To $519

The stock trades at about $350.16, and the at-the-money implied volatility on its options expiring roughly a year out is 38.9%. That prices a band running from a floor near $236 to a ceiling near $519. It is not a forecast. It is the range the market gives roughly a two-in-three chance of containing the price.

In money that is about $110 a share of downside and about $169 of upside. The gap is not a bullish tilt: a stock cannot fall below zero but can rise without limit, so the upper half of any band is wider in dollars.

ISRG Has Already Been Moving This Much

The width is normal for this stock now. Over the trailing year its realized volatility, how much it has actually moved, was 36.8%, so implied volatility of 38.9% is running at 1.06 times what the stock has already delivered. That is a modest premium that shows the market is pricing future swings largely in line with recent reality.

What holds volatility there is a set of questions on a slow clock. The U.S. da Vinci procedure growth slowed to 12% in Q2 2026 from 14% in Q1 2026. Management cited the law of large numbers alongside deferrable procedures, noting that the underlying disease burden is unchanged and patients eventually return, while CEO Rosa also relayed feedback from some customers that insurance coverage changes may be having an effect. An analyst pushed back, noting other med tech companies are not seeing the same effect.

GLP-1 use is shrinking US da Vinci bariatric cases at the same time. From the first half of 2027 the extended use program raises the number of uses on a subset of instruments, cutting what customers pay per procedure to support broader adoption where cost constrains it, and management has not put a number on the revenue impact yet. Customers are still taking the robots: da Vinci system placements rose 18% year over year in Q2 2026 on demand for da Vinci 5.

Size For The $240 Floor Before You Argue About The Ceiling

None of this says the business is coming apart. Revenue grew 20.7% over the trailing twelve months and the operating margin sits at a three-year peak. What the premium prices is how long the US procedure question and the instrument cost reset take to settle, and management describes that reset as a progressive impact through 2027 instead of a single step.

So the decision is about size, and the level to test yourself against is $240. A holder comfortable now who could not live with the stock sitting below $236 a year from now is carrying too much, because the market puts roughly a 16% chance on exactly that. Before you set that size, it is worth seeing where ISRG sits among stocks ranked by the size of the move their options are pricing.

The Options Market Is Telling You How Hard This Stock Can Swing

Options prices are telling you how hard this stock can move, and the professional response is to check how much of one name you hold before the swings arrive. That check is exactly what the Trefis Wealth team provides, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.